[Naproxen, a 'specific" antirheumatic drug?].
Inhibition of endonuclease by d-2-(6'-methoxy-2'-naphthyl)-propionic acid (naproxen) is discussed as a possible therapeutic principle of the antiinflammatory action in polyarthritis. Infections by 'slow viruses" and mycoplasma have to be considered as possible etiologic factors for rheumatoid arthritis. The incorporation of the viral or mycoplasmatic DNA into the genetic material of the host cell depends on the function of endonucleases, which can be inhibited by naproxen. The advantages and the drawbacks of this type of mechanism of action are discussed.
D001172:Arthritis, Rheumatoid / Q000188:drug therapy* / Q000209:etiology / Q000378:metabolism; D004269:DNA, Bacterial / Q000378:metabolism; D004279:DNA, Viral / Q000378:metabolism; D003864:Depression, Chemical; D004720:Endonucleases / Q000378:metabolism; D008954:Models, Biological; D009175:Mycoplasma Infections / Q000150:complications; D009280:Naphthaleneacetic Acids / Q000627:therapeutic use*; D009288:Naproxen / Q000627:therapeutic use*; D012897:Slow Virus Diseases / Q000150:complications
D004269:DNA, Bacterial; D004279:DNA, Viral; D009280:Naphthaleneacetic Acids; D009288:Naproxen; D004720:Endonucleases
Naprozen, ein 'spezifisches" Antirheumatikum?